Exelixis (EXEL) — insider trading
Health Care · NASDAQ
Exelixis (EXEL) has 32 reported SEC Form 4 insider transactions in our data, including 10 open-market sales among the most recent 32 (latest 2026-08-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Beckerle Mary C | Director | Open-market sale | 9,812 | $53.66 | $526.5K | Form 4 |
| 2026-06-01 | Eckhardt Sue Gail | Director | Open-market sale | 9,812 | $50.14 | $492.0K | Form 4 |
| 2026-06-01 | WYSZOMIERSKI JACK L | Director | Open-market sale | 3,925 | $50.55 | $198.4K | Form 4 |
| 2026-05-27 | JOHNSON DAVID EDWARD; Caligan Partners LP | Director | Grant / award / vesting (derivative) | 19,133 | — | $0 | Form 4 |
| 2026-05-27 | POSTE GEORGE | Director | Grant / award / vesting | 8,367 | — | $0 | Form 4 |
| 2026-05-27 | WYSZOMIERSKI JACK L | Director | Grant / award / vesting | 8,367 | — | $0 | Form 4 |
| 2026-05-27 | Oliver Bob | Director | Grant / award / vesting | 8,367 | — | $0 | Form 4 |
| 2026-05-27 | Beckerle Mary C | Director | Grant / award / vesting | 8,367 | — | $0 | Form 4 |
| 2026-05-27 | Freire Maria C | Director | Grant / award / vesting | 8,367 | — | $0 | Form 4 |
| 2026-05-27 | Smith Julie | Director | Grant / award / vesting | 8,367 | — | $0 | Form 4 |
| 2026-05-27 | Eckhardt Sue Gail | Director | Grant / award / vesting | 8,367 | — | $0 | Form 4 |
| 2026-05-27 | Heyman Tomas J. | Director | Grant / award / vesting | 8,367 | — | $0 | Form 4 |
| 2026-05-27 | PAPADOPOULOS STELIOS | Director | Grant / award / vesting | 8,367 | — | $0 | Form 4 |
| 2026-05-26 | Aftab Dana | Officer (EVP, Research and Development) | Open-market sale | 43,451 | $50.35 | $2.19M | Form 4 |
| 2026-05-20 | Haley Patrick J. | Officer (EVP, Commercial) | Open-market sale | 32,110 | $49.81 | $1.60M | Form 4 |
| 2026-05-18 | Hefti Brenda | Officer (SVP and General Counsel) | Open-market sale | 6,625 | $50.21 | $332.6K | Form 4 |
| 2026-05-18 | Senner Christopher J. | Officer (EVP and CFO) | Open-market sale | 34,901 | $50.00 | $1.75M | Form 4 |
| 2026-05-18 | MORRISSEY MICHAEL | Director, Officer (President and CEO) | Bona fide gift | 124,047 | — | $0 | Form 4 |
| 2026-05-18 | MORRISSEY MICHAEL | Director, Officer (President and CEO) | Bona fide gift | 124,047 | — | $0 | Form 4 |
| 2026-05-15 | Aftab Dana | Officer (EVP, Research and Development) | Shares withheld for taxes / exercise cost | 30,578 | $51.10 | $1.56M | Form 4 |
| 2026-05-15 | Hefti Brenda | Officer (SVP and General Counsel) | Shares withheld for taxes / exercise cost | 6,411 | $51.10 | $327.6K | Form 4 |
| 2026-05-15 | Haley Patrick J. | Officer (EVP, Commercial) | Shares withheld for taxes / exercise cost | 33,265 | $51.10 | $1.70M | Form 4 |
| 2026-05-15 | Senner Christopher J. | Officer (EVP and CFO) | Shares withheld for taxes / exercise cost | 40,892 | $51.10 | $2.09M | Form 4 |
| 2026-05-15 | MORRISSEY MICHAEL | Director, Officer (President and CEO) | Shares withheld for taxes / exercise cost | 128,497 | $51.10 | $6.57M | Form 4 |
| 2026-05-07 | POSTE GEORGE | Director | Open-market sale | 60,000 | $45.71 | $2.74M | Form 4 |
| 2026-05-07 | Freire Maria C | Director | Option exercise / conversion (derivative) | 20,634 | — | $0 | Form 4 |
| 2026-05-07 | Freire Maria C | Director | Open-market sale | 20,634 | $46.00 | $949.2K | Form 4 |
| 2026-05-07 | Freire Maria C | Director | Option exercise / conversion | 20,634 | $19.77 | $407.9K | Form 4 |
| 2026-05-07 | Beckerle Mary C | Director | Option exercise / conversion (derivative) | 3,856 | — | $0 | Form 4 |
| 2026-05-07 | Beckerle Mary C | Director | Open-market sale | 7,712 | $48.45 | $373.6K | Form 4 |
| 2026-05-07 | Beckerle Mary C | Director | Option exercise / conversion | 3,856 | $23.24 | $89.6K | Form 4 |
| 2026-05-06 | MORRISSEY MICHAEL | Director, Officer (President and CEO) | Bona fide gift | 109,676 | — | $0 | Form 4 |
Ask the chat about EXEL's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Exelixis (EXEL).
Last updated 2026-08-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.